Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Gains from Investment Securities (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Gains from Investment Securities for 15 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities rose 12.57% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Sep 2025, up 12.57%, and an annual FY2024 reading of $3.3 million, up 122.47% over the prior year.
  • Gains from Investment Securities was $2.2 million for Q3 2025 at BioRestorative Therapies, roughly flat from $2.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.2 million in Q1 2025 and bottomed at $25000.0 in Q1 2022.
  • Average Gains from Investment Securities over 5 years is $1.7 million, with a median of $1.2 million recorded in 2022.
  • The sharpest move saw Gains from Investment Securities skyrocketed 68916.46% in 2021, then plummeted 95.74% in 2022.
  • Year by year, Gains from Investment Securities stood at $838550.0 in 2021, then grew by 3.11% to $864639.0 in 2022, then surged by 69.65% to $1.5 million in 2023, then skyrocketed by 122.47% to $3.3 million in 2024, then crashed by 33.26% to $2.2 million in 2025.
  • Business Quant data shows Gains from Investment Securities for BRTX at $2.2 million in Q3 2025, $2.2 million in Q2 2025, and $5.2 million in Q1 2025.